Lista de obras - Marco Siccardi - Dominio Público Uruguay

A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.

artículo científico publicado en 2010

A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication

artículo científico publicado en 2014

A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting.

artículo científico publicado en 2008

A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method

artículo científico publicado en 2006

A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients.

artículo científico publicado en 2010

An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients

artículo científico publicado en 2008

Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation

artículo científico publicado en 2013

Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.

artículo científico

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

artículo científico publicado en 2012

Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir

artículo científico publicado en 2008

Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles

artículo científico publicado en 2015

Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.

artículo científico publicado en 2015

CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.

artículo científico publicado en 2014

CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.

artículo científico publicado en 2014

Ceftriaxone bone penetration in patients with septic non-union of the tibia

scientific article published on 15 April 2011

Class-specific relative genetic contribution for key antiretroviral drugs

artículo científico publicado en 2015

Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject

artículo científico publicado en 2007

Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor

artículo científico publicado en 2013

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens

artículo científico publicado en 2011

Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics

artículo científico publicado en 2012

Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma

artículo científico publicado en 2009

Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices

artículo científico publicado en 2016

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.

artículo científico publicado en 2014

Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

artículo científico publicado en 2010

Divalent metals and pH alter raltegravir disposition in vitro

artículo científico publicado en 2012

Efavirenz in an obese HIV-infected patient – a report and an in vitro–in vivo extrapolation model indicate risk of underdosing

article

Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations.

artículo científico publicado en 2011

Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions

Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia.

artículo científico publicado en 2008

HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions

artículo científico publicado en 2010

HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.

artículo científico publicado en 2007

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults

artículo científico publicado en 2015

Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.

artículo científico publicado en 2010

Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.

artículo científico publicado en 2012

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals

artículo científico publicado en 2011

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter

artículo científico publicado en 2015

Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells

artículo científico publicado en 2012

Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting

Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.

artículo científico publicado en 2009

Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism

artículo científico publicado en 2010

Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry

artículo científico publicado en 2015

Nanomedicines for HIV therapy

artículo científico publicado en 2013

Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment.

artículo científico publicado en 2012

Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.

artículo científico

Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling

artículo científico publicado en 2014

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model

artículo científico publicado en 2012

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study

artículo científico publicado en 2011

Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients

article

Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.

artículo científico publicado en 2015

Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective

Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance

artículo científico publicado en 2010

Predicting intestinal absorption of raltegravir using a population-based ADME simulation

artículo científico publicado en 2013

Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach

artículo científico publicado en 2013

Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population

artículo científico publicado en 2012

Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir

artículo científico publicado en 2010

Raltegravir penetration in seminal plasma of healthy volunteers

artículo científico publicado en 2010

Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4.

artículo científico publicado en 2011

Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro

artículo científico publicado en 2013

Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.

artículo científico publicado en 2015

Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV.

artículo científico publicado en 2009

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).

artículo científico publicado en 2015

The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon

artículo científico publicado en 2008

Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.

artículo científico publicado en 2007

Unexpected drug–drug interaction between tipranavir/ritonavir and enfuvirtide

artículo científico publicado en 2006

Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.

artículo científico publicado en 2015

Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots.

artículo científico publicado en 2015

Validation of Computational Approaches for Antiretroviral Dose Optimization

artículo científico publicado en 2016

Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds

artículo científico publicado en 2010

Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients

artículo científico publicado en 2006

Lista de obras de Marco Siccardi

A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.

A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication

A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting.

A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method

A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients.

An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients

Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation

Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir

Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles

Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.

CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.

CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.

Ceftriaxone bone penetration in patients with septic non-union of the tibia

Class-specific relative genetic contribution for key antiretroviral drugs

Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject

Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens

Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics

Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma

Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.

Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Divalent metals and pH alter raltegravir disposition in vitro

Efavirenz in an obese HIV-infected patient – a report and an in vitro–in vivo extrapolation model indicate risk of underdosing

Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations.

Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions

Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia.

HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions

HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults

Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.

Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter

Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells

Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting

Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.

Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism

Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry

Nanomedicines for HIV therapy

Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment.

Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.

Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study

Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients

Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.

Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective

Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance

Predicting intestinal absorption of raltegravir using a population-based ADME simulation

Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach

Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population

Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir

Raltegravir penetration in seminal plasma of healthy volunteers

Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4.

Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro

Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.

Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV.

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).

The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon

Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.

Unexpected drug–drug interaction between tipranavir/ritonavir and enfuvirtide

Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.

Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots.

Validation of Computational Approaches for Antiretroviral Dose Optimization

Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds

Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients